Differential Diagnostics of Etiology of Acute Infections
NCT ID: NCT03161951
Last Updated: 2019-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
169 participants
OBSERVATIONAL
2017-01-03
2018-12-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Involvement of Polymorphonuclear Neutrophils and Platelets in Severe Form of COVID-19
NCT04930757
Monocytes and NK Cells Activity in Covid-19 Patients
NCT04375176
Rapid Analysis of Infections by Spectrometry of Exhaled Breath
NCT03299608
Efficacy and Safety of a Protocol Using C-reactive Protein to Guide Antibiotic Therapy
NCT05841875
Assessment of the Effectiveness of a Prototype Diagnostic System of Bacterial Respiratory Infections Based on Real-time Sequencing
NCT07303400
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The expression of the following markers of activation will be studied using flow cytometry: CD11b, CD11c, CD13, CD16, CD32, CD35, CD38, CD62L, CD64, CD66b, CD88, CD284, HLA-ABC and HLA-DR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neuroinfections
Patients with acute neuroinfections of bacterial and viral ethology.
No interventions assigned to this group
Intestinal Infectious Diseases
Patients with acute intestinal infectious diseases of bacterial and viral ethology.
No interventions assigned to this group
Control group
Control group of healthy persons
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* the possibility of blood sampling within a period of up to 24 hours from the moment of admission to hospital;
* less than 72 hours passed after the onset of the disease and until blood was collected;
Exclusion Criteria
* more than 24 hours passed after the patient entered the hospital;
* the disease began more than 72 hours ago;
* concomitant severe acute and chronic diseases;
* malignant neoplasms, treatment at a time of less than 1 year, autoimmune diseases in the phase of exacerbation;
* pregnancy/lactation;
* HIV, Hepatites B/C;
* active tuberculosis;
* alcohol use disorder/drug addiction.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Republican Research and Practical Center for Epidemiology and Microbiology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrei Y. Hancharou
Head of the Laboratory for Immunology and Cellular Biotechnology,
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrei Y Hancharou, Dr
Role: STUDY_DIRECTOR
Head of the Laboratory for Immunology and Cellular Biotechnology, The Republican Research and Practical Center for Epidemiology and Microbiology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RRPCEM_NMAT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.